Komen Columbus Goes to D.C.

Mission Programs Manager Lauren Beitel, the 2018 Komen Columbus Honorary Race Chair Liz Miesen and Director of Communications Becca Thomas attended the summit.

Last week a few of our staff members were fortunate enough to attend the Komen Advocacy Summit in Washington, D.C. We spent a day meeting with our congresspeople and senators and had three primary asks:

  1. To preserve women’s access to breast cancer screening and diagnostic services by funding the National Breast and Cervical Cancer Early Detection Program. At current funding levels, this program serves less than 10 percent of the estimated number of eligible women.
  2. It’s possible we’ll see 250,000 new cases of #breastcancer this year. We need Congress to make biomedical research a priority by increasing funding in the FY18 and FY19 budgets.
  3. IV drug therapy is the most well-known component of cancer treatment, but an increasing number of cancer drugs can be administered orally. Insurance coverage has not kept pace with innovation and the result is patient cost for these types of therapies can be significantly higher. We need our members of Congress to reduce the unnecessary burdens in accessing quality care by limiting patients’ out-of-pocket costs for specialty-tiered medications by becoming a cosponsor of the Patients Access to Treatment Act of 2017.

IMG_7485We are honored to be a voice for the more than 3.1 million breast cancer survivors and those who love them, working to ensure that the fight against breast cancer is a priority among policymakers in Washington, D.C. Each year, Komen works to identify, through a transparent and broad-based, intensive vetting and selection process, the advocacy issues that have the greatest potential impact on Komen’s mission. This process includes the collection of feedback from Komen Headquarters leadership, advocacy staff, and subject matter experts; Komen Affiliates from across the country; advisory groups including the Komen Advocacy Advisory Taskforce, Advocates in Science, and Komen Scholars; and other stakeholders with a vested interest in breast cancer-related issues.